Skip to content

Trial · Interventional

CompletedPhase 1Results postedRegistry data

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

NCTNCT04081337 (opens ClinicalTrials.gov in a new tab)Other id17092Other idI8F-MC-GPGU

Overview

Status
Completed
Phase
Phase 1
Enrollment
55 participants (actual)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Double masking
Countries
1 country

United States

Start
9 Jul 2020
Primary completion
26 May 2022
Completion
26 May 2022
First posted
9 Sept 2019
Last update posted
8 Feb 2024
Conditions
Obesity

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2020202120222023
  1. Ph 1

    A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

    NCT04081337

    9 Jul 2020 to 26 May 2022

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.

Interventions

  • TirzepatideDrug
  • PlaceboDrug

Arms2

  • Placebo comparator

    Placebo

    Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.

  • Experimental

    15 Milligram (mg) Tirzepatide

    Participants received 15 mg of tirzepatide QW by SC injection.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)

    Time frame · Baseline, Week 18

    Registry description

    SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

Secondary outcomes(15)
  1. Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal

    Time frame · Baseline, Week 18

    Registry description

    Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  2. Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)

    Time frame · Baseline, Week 18

    Registry description

    24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

  3. Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)

    Time frame · Baseline, Week 18

    Registry description

    Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 \[Liter/24hour\] / total VO2 \[Liter/24hour\]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  4. Change From Baseline to Week 18 in Sleep RQ

    Time frame · Baseline, Week 18

    Registry description

    Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  5. Change From Baseline to Week 18 in Duration of Periods With RQ<0.80

    Time frame · Baseline, Week 18

    Registry description

    RQ\<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ \<0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  6. Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation

    Time frame · Baseline, Week 18

    Registry description

    Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented. * Protein Oxidation = 6.25\*\[urinary nitrogen\] * Fat Oxidation = 1.689\*\[total oxygen consumption (VO2)\] - 1.689\*\[total carbon dioxide production (VCO2)\] - 0.324\*\[protein oxidation\] * Carbohydrate Oxidation = 4.113\*\[VCO2\] - 2.907\*\[VO2\] - 0.375\*\[protein oxidation\]. Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  7. Change From Baseline to Week 18 in Body Weight (BW)

    Time frame · Baseline, Week 18

    Registry description

    Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

  8. Change From Baseline to Week 18 in Body Fat-Free Mass

    Time frame · Baseline, Week 18

    Registry description

    Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  9. Change From Baseline to Week 18 in Body Fat Mass

    Time frame · Baseline, Week 18

    Registry description

    Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  10. Change From Baseline to Week 18 in Percentage of Body Fat Mass

    Time frame · Baseline, Week 18

    Registry description

    The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  11. Change From Baseline to Week 18 in Lipid Metabolism Parameters

    Time frame · Baseline, Week 18

    Registry description

    Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  12. Change From Baseline to Week 18 in Fasting Insulin Resistance

    Time frame · Baseline, Week 18 during standardized mixed meal tolerance test

    Registry description

    Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= \[Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)\] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  13. Change From Baseline to Week 18 in Postprandial Insulin Sensitivity

    Time frame · Baseline, Week 18

    Registry description

    Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of \<2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  14. Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT

    Time frame · Baseline, Week 18

    Registry description

    Total AUC from time zero to 4 hours after start of the meal \[AUC0-4 hours\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

  15. Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)

    Time frame · Baseline, Week 18

    Registry description

    HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)

GroupValue (kilocalories per day (kcal/day))Spread
Placebo-154.3619.69
15 mg Tirzepatide-134.6821.62
Secondary and other outcome results(7)
Secondary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal

GroupValue (kilocalories (kcal))Spread
Placebo-58.5782.29
15 mg Tirzepatide-914.5182.29
Secondary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)

GroupValue (kcal/day)Spread
Placebo-296.8527.67
15 mg Tirzepatide-300.0730.44
Secondary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)

GroupValue (Ratio)Spread
Placebo0.0050.005
15 mg Tirzepatide-0.0300.006
Secondary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in Sleep RQ

GroupValue (ratio)Spread
Placebo-0.0010.006
15 mg Tirzepatide-0,0280.006
Secondary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in Duration of Periods With RQ<0.80

GroupValue (minute)Spread
Placebo2.5543.97
15 mg Tirzepatide254.4447.14
Secondary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation

GroupValue (gram/day)Spread
Placebo-0.141.23
15 mg Tirzepatide-7.001.32
Secondary outcomeLeast squares mean· Baseline, Week 18

Change From Baseline to Week 18 in Body Weight (BW)

GroupValue (kilogram (kg))Spread
Placebo-8.260.90
15 mg Tirzepatide-16.730.92

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
PlaceboParticipants received placebo once weekly by SC injection.0 / 280 / 2819 / 28
15 mg TirzepatideParticipants received 15 mg of tirzepatide once weekly by subcutaneous injection.0 / 271 / 2722 / 27

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 60 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Have body mass index of 30 to 45 kilograms per square meter (kg/m²), inclusive * Have a stable body weight in the past 1 month prior to screening * Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff Exclusion Criteria: * Have undergone gastric bypass or bariatric surgery * Have a diagnosis of type 2 diabetes * Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data * Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening * Have any lifetime history of a suicide attempt * Patient Health Questionnaire-9 (PHQ-9) score of 15 or more at screening * Positive responses to selected items on the Columbia Suicide Severity Rating Scale (C-SSRS)

PepBank is a research reference. Talk to a doctor before you use any peptide.